Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Jonathan Stine
Modality
protein_peptide
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04055389CT.gov Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Portal Vein Thrombosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Antithrombin Iii (this asset) | Jonathan Stine | P1 | CC · 41 |
| Sorafenib | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Lenvatinib | First Hospital of China Medical University | P4 | BBB |
| Warfarin | Kafrelsheikh University | P4 | BB |
| Nadroparin | Shanghai Zhongshan Hospital | P4 | BB |
| Enoxaparin | Institute of Liver and Biliary Sciences, India | P4 | BB |
| Apixaban | Asian Institute Of Medical Sciences | P4 | B |
| Carvedilol | Asian Institute Of Medical Sciences | P4 | B |
| Absorbable Gelatin Sponge | Shanghai Zhongshan Hospital | P3 | B |
+18 more in the Portal Vein Thrombosis cohort
Other indications for Antithrombin Iii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia A | — | P4 | B · 59 |
| Hemophilia | — | P3 | B · 57 |
| Cirrhosis Of Liver | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Antithrombin Iii in Portal Vein Thrombosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/antithrombin-iii-portal-vein-thrombosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →